CD274 and neoplasm: Programmed death-ligand 1 (PD-L1) is a predictive biomarker used to guide treatment decisions for its expression is associated with an increased likelihood of response to programmed death-1 (PD-1) pathway blockade, but responses to immune checkpoint inhibitors (ICIs) can also be seen in patients with no tumor PD-L1 expression.